Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.10%, a 2.50% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 9.30% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.80%, a 2.70% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.00%, a 11.11% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.20%, a 0.00% change from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 5.00% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 60.00% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.50%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 4.10% 10-Q · filed 2026-08-04 | 3.90% 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 4.20% 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 3.80% 10-Q · filed 2025-11-05 | 4.20% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 4.00% 10-Q · filed 2026-08-04 | 4.30% 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | 4.30% 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | 4.20% 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 3.70% 10-Q · filed 2025-11-05 | 4.20% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-07 | 4.30% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | 4.30% 10-Q · filed 2024-11-07 | 3.90% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 4.10% 10-Q · filed 2024-08-08 | 3.80% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.60% 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 2.50% 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | 3.10% 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | 1.20% 8-K · filed 2023-12-21 | 0.90% 10-K · filed 2022-03-08 | |||
| 2020-12-31 | 1.00% 10-K · filed 2022-03-08 | ||||
| 2019-12-31 | 2.30% 10-K · filed 2021-03-03 | ||||
| 2018-12-31 | 2.80% 10-K · filed 2020-03-03 | ||||
| 2017-12-31 | 2.00% 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |